2017 Annual Meeting

International Society of Bone and Soft Tissue Pathology

March 5 2017, 1:30pm to 5:00pm

Description

International Society of Bone and Soft Tissue Pathology

Tumor Syndromes in Bone and Soft Tissue Pathology

Sunday, March 5, 2017
1:30 PM 5:00 PM
CC 301

 

Session Credits: 3 CME and 3 SAMs

Moderators: Julia Bridge, MD, Nebraska Health System, Omaha, Nebraska
Judith VMG Bove, MD, PhD, Leiden University Medical Center, Leiden, The Netherlands

Course Description:
Hereditary etiologies corresponding to Mendelian inheritance principles, in addition to congenital malformation syndromes lacking a clear inheritance pattern, have increasingly been recognized as responsible for a subset of bone and soft tissue tumor diagnoses in children and adults. A continuing rise in the identification of cancer-causing germline mutations for which molecular testing is available, coupled with a heightened awareness of the importance of a detailed family history for sarcoma patients, has improved diagnosis, prevention, surveillance, and therapy for affected families. The genetic breakthroughs that have resulted from the investigation of inherited cancer syndromes have not only benefited patients with heritable tumor predisposition but have also shed light on the regulatory molecular pathways in sporadic tumors thereby advancing the care of sarcoma patients without known risk factors too. These discoveries continue to expand the role of the surgical pathologist in the multidisciplinary care of patients with these neoplasms. In this companion meeting, new developments as well as current principles of molecular and surgical pathology in bone and soft tissue tumors (heritable and sporadic counterparts) and their application to the clinical management of these neoplasms will be emphasized.
The symposium theme and content are selected by the President with input from the executive officers of the International Society of Bone and Soft Tissue Pathology. The agenda has been designed to meet the educational needs of general surgical pathologists as well as bone and soft tissue tumor subspecialists who are involved in the management of patients with mesenchymal neoplasms.

Upon completion of this educational activity, participants should be better able to:

  • Recognize recent developments in genomics of sarcomas arising in hereditary and sporadic settings 
  • Describe the role of germline/somatic biomarkers in the diagnostic classification, prognostication, and/or management of sarcomas that may arise
  • Associate clinicomorphologic variants with specific genetic changes

 

Agenda

1:30 PM

Welcome; Tumor Syndromes in Bone and Soft Tissue Pathology
Judith VMG Bove, MD, PhD, Leiden University Medical Center, Leiden, The Netherlands

1:35 PM

Neurofibromatosis Type 1 Syndrome and Associated Tumors
Steven L. Carroll, MD, PhD, Medical University of South Carolina, Charleston, SC

2:10 PM

Tumor Syndromes Predisposing to Osteosarcoma
Meera R. Hameed, MD, Memorial Sloan-Kettering Cancer Center, New York, NY

2:35 PM

GNAS Related Mesenchymal Tumors
Gene P. Siegal, MD, PhD, University of Alabama, Birmingham, AL

3:00 PM

Break

3:30 PM

Metabolic Enzymes (IDH, FH, SDH) and Mesenchymal Tumor (Syndrome)s
Judith VMG Bove, MD, PhD, Leiden University Medical Center, Leiden, The Netherlands

4:05 PM

Familial Adenomatous Polyposis and Associated Mesenchymal Tumors
Cheryl M. Coffin, MD

4:30 PM

Concluding Remarks

Meetings

home-circle-inset-1
view more